Dianthus Therapeutics’ (DNTH) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report released on Tuesday,Benzinga reports. The firm currently has a $40.00 price objective on the stock.

Several other equities research analysts also recently commented on DNTH. Guggenheim reaffirmed a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Buy” and a consensus price target of $53.00.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $18.84 on Tuesday. The company’s 50 day simple moving average is $19.68 and its 200 day simple moving average is $22.30. Dianthus Therapeutics has a fifty-two week low of $13.37 and a fifty-two week high of $32.27. The firm has a market capitalization of $605.25 million, a P/E ratio of -7.54 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $26,000. KLP Kapitalforvaltning AS bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $33,000. US Bancorp DE increased its position in shares of Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares in the last quarter. KBC Group NV bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth $59,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.